|Poll|August 21, 2014

Mini-quiz: Electroencephalogram Abnormalities in Psychiatric Patients

Compared with healthy controls, is the prevalence of EEG abnormalities in psychiatric patients different than in healthy controls? Take the quiz and learn more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

ByErica Taylor, MD, MPH,Drew Cumming, MD,James A. Bourgeois, OD, MD

October 24th 2025

Dr Max Fink, Farewell and Thank You

ByHoracio A. Capote, MD

October 16th 2025

Addressing Cognition in Late-Life Depression

ByJoshua J. Hubregsen, MD,Andre R. Brunoni, MD, PhD,Molly E. Camp, MD,Tarek K. Rajji, MD

October 1st 2025

Dr Max Fink, Farewell and Thank You!

ByHoracio A. Capote, MD

August 27th 2025

The Double-Edged Sword of Affluence

ByDanielle Egbe, DO,Christina B. Smith, MD

May 12th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Mini-quiz: Electroencephalogram Abnormalities in Psychiatric Patients

Newsletter

Related Content

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

Dr Max Fink, Farewell and Thank You

Addressing Cognition in Late-Life Depression

Dr Max Fink, Farewell and Thank You!

The Double-Edged Sword of Affluence

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

What Happened to Psychopathology?

Psychiatry Wrapped 2025: Year in Review